Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT02441686 |
Title | Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma |
Recruitment | Active, not recruiting |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Dana-Farber Cancer Institute |
Indications | |
Therapies | |
Age Groups: | adult |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
Colorado Blood Cancer Institute | Denver | Colorado | 80218 | United States | Details | |
Eastern Maine Medical Center | Brewer | Maine | 04412 | United States | Details | |
Massachusetts General Hosptial | Boston | Massachusetts | 02114 | United States | Details | |
Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | United States | Details | |
Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | United States | Details | |
Virginia Piper Cancer Institute | Coon Rapids | Minnesota | 55433 | United States | Details | |
Virgina Piper Cancer Institute | Minneapolis | Minnesota | 55407 | United States | Details | |
Hematology Oncology of Northern New Jersey | Morristown | New Jersey | 07962 | United States | Details |